Alessandro Colombo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alessandro Colombo has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Maurizio Viecca
Cardiology Department, "Luigi Sacco" Hospital, Milano, Italy
4 shared publicationsGiuseppe Alessandrino
Cardiology Department, "Luigi Sacco" Hospital, Milano, Italy
2 shared publicationsMarco Schiavone
Cardiology Department, "Luigi Sacco" Hospital, Milano, Italy
2 shared publicationsMaurizio Di Biasi
Cardiology Department, "Luigi Sacco" Hospital, Milano, Italy
2 shared publicationsPaolo Danna
Cardiology Department, "Luigi Sacco" Hospital, Milano, Italy
2 shared publicationsVincenzo Vizzi
Cardiology Department, "Luigi Sacco" Hospital, Milano, Italy
2 shared publications
Latest Publications
- 2 February 2023
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 49, 72
The Evolving Field of Left Mammary Graft Angiography Through Right Radial Access
- 2 February 2023
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 49, 72
The Evolving Field of Left Mammary Graft Angiography Through Right Radial Access
- 7 June 2022
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 44, 21-29
Comparing Left Internal Mammary Angiography via Right Radial or Femoral Access With a Single-Catheter Technique
- 7 June 2022
- Published by Elsevier in Cardiovascular Revascularization Medicine
- Vol. 44, 21-29
Comparing Left Internal Mammary Angiography via Right Radial or Femoral Access With a Single-Catheter Technique
- 1 May 2017
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 10 (10) , 1063-1065
The Striking Interplay of Hiccup and Patent Foramen Ovale
- 1 May 2017
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 10 (10) , 1063-1065
The Striking Interplay of Hiccup and Patent Foramen Ovale
- 1 April 2011
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 12 (4) , 239-248
Myocardial blood flow and infarct size after CD133+ cell injection in large myocardial infarction with good recanalization and poor reperfusion: results from a randomized controlled trial
Large acute ST-elevation myocardial infarction (STEMI) sometimes leaves extensive ischemic damage despite timely and successful primary angioplasty. This clinical picture of good recanalization with incomplete reperfusion represents a good model to assess the reparative potential of locally administered cell therapy. Thus, we conducted a randomized controlled trial aimed at evaluating the effect of intracoronary administration of CD133 stem cells on myocardial blood flow and function in this setting. Fifteen patients with large anterior STEMI, myocardial blush grade 0-1 and more than 50% ST-elevation recovery after optimal coronary recanalization (TIMI 3 flow) with stenting were randomly assigned to receive CD133 cells from either bone marrow (group A) or peripheral blood (group B), or to stay on drug therapy alone (group C). The cells were intracoronary injected within 10-14 days of STEMI. Infarct-related myocardial blood flow (MBF) was evaluated by NH positron emission tomography 2-5 days before cell administration and after 1 year. MBF increased in the infarct area from 0.419 (0.390-0.623) to 0.544 (0.371-0.729) ml/min per g in group A, decreased from 0.547 (0.505-0.683) to 0.295 (0.237-0.472) ml/min per g in group B and only slightly changed from 0.554 (0.413-0.662) to 0.491 (0.453-0.717) ml/min per g in group C (A vs. C: P = 0.023; B vs. C: P = 0.066). Left ventricular volume tended to increase more in groups B and C than in group A, ejection fraction and wall motion score index remained stable in the three groups. These findings support the hypothesis that intracoronary administration of bone marrow-derived, but not peripheral blood-derived CD133 cells 10-14 days after STEMI may improve long-term perfusion.
- 1 April 2011
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 12 (4) , 239-248
Myocardial blood flow and infarct size after CD133+ cell injection in large myocardial infarction with good recanalization and poor reperfusion: results from a randomized controlled trial
Large acute ST-elevation myocardial infarction (STEMI) sometimes leaves extensive ischemic damage despite timely and successful primary angioplasty. This clinical picture of good recanalization with incomplete reperfusion represents a good model to assess the reparative potential of locally administered cell therapy. Thus, we conducted a randomized controlled trial aimed at evaluating the effect of intracoronary administration of CD133 stem cells on myocardial blood flow and function in this setting. Fifteen patients with large anterior STEMI, myocardial blush grade 0-1 and more than 50% ST-elevation recovery after optimal coronary recanalization (TIMI 3 flow) with stenting were randomly assigned to receive CD133 cells from either bone marrow (group A) or peripheral blood (group B), or to stay on drug therapy alone (group C). The cells were intracoronary injected within 10-14 days of STEMI. Infarct-related myocardial blood flow (MBF) was evaluated by NH positron emission tomography 2-5 days before cell administration and after 1 year. MBF increased in the infarct area from 0.419 (0.390-0.623) to 0.544 (0.371-0.729) ml/min per g in group A, decreased from 0.547 (0.505-0.683) to 0.295 (0.237-0.472) ml/min per g in group B and only slightly changed from 0.554 (0.413-0.662) to 0.491 (0.453-0.717) ml/min per g in group C (A vs. C: P = 0.023; B vs. C: P = 0.066). Left ventricular volume tended to increase more in groups B and C than in group A, ejection fraction and wall motion score index remained stable in the three groups. These findings support the hypothesis that intracoronary administration of bone marrow-derived, but not peripheral blood-derived CD133 cells 10-14 days after STEMI may improve long-term perfusion.
- 1 March 2009
- Published by Elsevier in The Lancet
- Vol. 373 (9667) , 872-3
The ischaemia/bleeding balance in PCI.
- 1 March 2009
- Published by Elsevier in The Lancet
- Vol. 373 (9667) , 872-3
The ischaemia/bleeding balance in PCI.
- 1 September 2002
- Vol. 3 (9) , 532-3
Angiographic evidence of myocardial channels after percutaneous transmyocardial laser treatment.
The available clinical reports on percutaneous transmyocardial laser revascularization do not provide data on the visibility of the channels after the procedures. We present the case of a patient who had clear angiographic evidence of the presence of myocardial channels immediately after percutaneous transmyocardial laser revascularization.
- 1 September 2002
- Vol. 3 (9) , 532-3
Angiographic evidence of myocardial channels after percutaneous transmyocardial laser treatment.
The available clinical reports on percutaneous transmyocardial laser revascularization do not provide data on the visibility of the channels after the procedures. We present the case of a patient who had clear angiographic evidence of the presence of myocardial channels immediately after percutaneous transmyocardial laser revascularization.